Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.

Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, Nicholls SJ, Shah PK, Tardif JC, Olsson AG, McMurray JJ, Kittelson J, Schwartz GG.

J Am Heart Assoc. 2017 Jan 10;6(1). pii: e004119. doi: 10.1161/JAHA.116.004119.

2.

Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?

Masoumi A, Ortiz F, Radhakrishnan J, Schrier RW, Colombo PC.

Heart Fail Rev. 2015 May;20(3):283-90. doi: 10.1007/s10741-014-9467-2. Review.

3.

3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2.

Yin L, Hu Q, Hartmann RW.

PLoS One. 2012;7(11):e48048. doi: 10.1371/journal.pone.0048048. Epub 2012 Nov 1.

4.

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.

Nappi JM, Sieg A.

Vasc Health Risk Manag. 2011;7:353-63. doi: 10.2147/VHRM.S13779. Epub 2011 Jun 8. Review.

5.

Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells.

Godfrey V, Martin AL, Struthers AD, Lyles GA.

Br J Pharmacol. 2011 Dec;164(8):2003-14. doi: 10.1111/j.1476-5381.2011.01523.x.

6.

Drug mechanisms to help in managing resistant hypertension in obesity.

Jansen PM, Danser JA, Spiering W, van den Meiracker AH.

Curr Hypertens Rep. 2010 Aug;12(4):220-5. doi: 10.1007/s11906-010-0123-5. Review.

7.

Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts.

van Esch JH, Gembardt F, Sterner-Kock A, Heringer-Walther S, Le TH, Lassner D, Stijnen T, Coffman TM, Schultheiss HP, Danser AH, Walther T.

Cardiovasc Res. 2010 Jun 1;86(3):401-9. doi: 10.1093/cvr/cvq004. Epub 2010 Jan 12.

8.
9.

Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.

Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, Fogo AB, Brown NJ.

Kidney Int. 2009 May;75(9):936-44. doi: 10.1038/ki.2009.9. Epub 2009 Feb 18.

11.

Why are mineralocorticoid receptor antagonists cardioprotective?

Chai W, Danser AH.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Dec;374(3):153-62. Epub 2006 Oct 31. Review.

Supplemental Content

Support Center